Ryan K Dare1, Chad Tewell2, Bryan Harris3, Patty W Wright3, Sara L Van Driest4,5, Eric Farber-Eger6, George E Nelson3, Thomas R Talbot3. 1. Division of Infectious Diseases, Department of Medicine, University of Arkansas for Medical Sciences, Little Rock. 2. St Vincent Health, Indianapolis, Indiana. 3. Division of Infectious Diseases, Department of Medicine, Nashville, Tennessee. 4. Division of General Pediatrics, Department of Pediatrics, Nashville, Tennessee. 5. Division of Clinical Pharmacology, Department of Medicine, Nashville, Tennessee. 6. Vanderbilt Institute for Clinical and Translational Research, Vanderbilt University Medical Center, Nashville, Tennessee.
Abstract
Background: Daptomycin-associated myopathy has been identified in 2%-14% of patients, and rhabdomyolysis is a known adverse effect. Although risk factors for daptomycin-associated myopathy are poorly defined, creatine phosphokinase (CPK) monitoring and temporary discontinuation of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, or "statins," has been recommended. Methods: We conducted a single-center, retrospective, matched case-control risk factor analysis in adult and pediatric patients from 2004 to 2015. Patients in whom myopathy (defined as CPK values above the upper limit of normal) developed during daptomycin treatment were matched 1:1 to no-myopathy controls with at least the same duration of therapy. Risk factors independently associated with myopathy were determined using multivariable conditional logistic regression. Secondary analysis was performed in patients with rhabdomyolysis, defined as CPK values ≥10 times the upper limit of normal. Results: Of 3042 patients reviewed, 128 (4.2%) were identified as having daptomycin-associated myopathy, 25 (0.8%) of whom had rhabdomyolysis; 121 (95%) of the 128 were adults, and the mean duration of therapy before CPK elevation was 16.7 days (range, 1-58 days). In multivariate analysis, deep abscess treatment (odds ratio, 2.80; P = .03), antihistamine coadministration (3.50; P = .03), and statin coadministration (2.60; P = .03) were independent risk factors for myopathy. Obesity (odds ratio, 3.28; P = .03) and statin coadministration (4.67; P = .03) were found to be independent risk factors for rhabdomyolysis, and older age was associated with reduced risk (0.97; P = .05). Conclusions: Statin coadministration with daptomycin was independently associated with myopathy and rhabdomyolysis. This is the first study to provide strong evidence supporting this association. During coadministration, we recommend twice-weekly CPK monitoring and consideration of withholding statins.
Background: Daptomycin-associated myopathy has been identified in 2%-14% of patients, and rhabdomyolysis is a known adverse effect. Although risk factors for daptomycin-associated myopathy are poorly defined, creatine phosphokinase (CPK) monitoring and temporary discontinuation of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, or "statins," has been recommended. Methods: We conducted a single-center, retrospective, matched case-control risk factor analysis in adult and pediatric patients from 2004 to 2015. Patients in whom myopathy (defined as CPK values above the upper limit of normal) developed during daptomycin treatment were matched 1:1 to no-myopathy controls with at least the same duration of therapy. Risk factors independently associated with myopathy were determined using multivariable conditional logistic regression. Secondary analysis was performed in patients with rhabdomyolysis, defined as CPK values ≥10 times the upper limit of normal. Results: Of 3042 patients reviewed, 128 (4.2%) were identified as having daptomycin-associated myopathy, 25 (0.8%) of whom had rhabdomyolysis; 121 (95%) of the 128 were adults, and the mean duration of therapy before CPK elevation was 16.7 days (range, 1-58 days). In multivariate analysis, deep abscess treatment (odds ratio, 2.80; P = .03), antihistamine coadministration (3.50; P = .03), and statin coadministration (2.60; P = .03) were independent risk factors for myopathy. Obesity (odds ratio, 3.28; P = .03) and statin coadministration (4.67; P = .03) were found to be independent risk factors for rhabdomyolysis, and older age was associated with reduced risk (0.97; P = .05). Conclusions: Statin coadministration with daptomycin was independently associated with myopathy and rhabdomyolysis. This is the first study to provide strong evidence supporting this association. During coadministration, we recommend twice-weekly CPK monitoring and consideration of withholding statins.
Authors: Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde Journal: J Biomed Inform Date: 2008-09-30 Impact factor: 6.317
Authors: F B Oleson; C L Berman; J B Kirkpatrick; K S Regan; J J Lai; F P Tally Journal: Antimicrob Agents Chemother Date: 2000-11 Impact factor: 5.191
Authors: P Brandon Bookstaver; Christopher M Bland; Zaina P Qureshi; Carmen M Faulkner-Fennell; Margrit A Sheldon; Celeste R Caulder; Charles Hartis Journal: Pharmacotherapy Date: 2013-05-26 Impact factor: 4.705
Authors: Anthony M Casapao; Ravina Kullar; Susan L Davis; Donald P Levine; Jing J Zhao; Brian A Potoski; Debra A Goff; Christopher W Crank; John Segreti; George Sakoulas; Sara E Cosgrove; Michael J Rybak Journal: Antimicrob Agents Chemother Date: 2013-06-17 Impact factor: 5.191
Authors: Manjunath P Pai; Jeffrey P Norenberg; Tamara Anderson; Diane W Goade; Keith A Rodvold; Robert A Telepak; Renee-Claude Mercier Journal: Antimicrob Agents Chemother Date: 2007-06-04 Impact factor: 5.191
Authors: R Andrew Seaton; Francesco Menichetti; Georgios Dalekos; Andres Beiras-Fernandez; Francisco Nacinovich; Rashidkhan Pathan; Kamal Hamed Journal: Adv Ther Date: 2015-11-26 Impact factor: 3.845
Authors: D C Richter; T Brenner; A Brinkmann; B Grabein; M Hochreiter; A Heininger; D Störzinger; J Briegel; M Pletz; M A Weigand; C Lichtenstern Journal: Anaesthesist Date: 2019-10 Impact factor: 1.041
Authors: Ashley N Fox; Winter J Smith; Katherine E Kupiec; Stephanie J Harding; Beth H Resman-Targoff; Stephen B Neely; Bryan P White; Ryan E Owens Journal: Ther Adv Infect Dis Date: 2019-01-30